Restricted accessReview articleFirst published online 2023-7
Bayesian Meta-analysis of Direct Oral Anticoagulation Versus Vitamin K Antagonists With or Without Concomitant Antiplatelet After Transcatheter Aortic Valve Implantation in Patients With Anticoagulation Indication
Patients undergoing transcatheter aortic valve implantation (TAVI) commonly have co-morbidities requiring anticoagulation. However, the optimal post-procedural anticoagulation regimen is not well-established. This meta-analysis investigates safety and efficacy outcomes of direct oral anticoagulants (DOACs) and Vitamin K Antagonist (VKA), with or without concomitant antiplatelet therapy. We searched EMBASE and MEDLINE for appropriate studies. Subgroup analyses were performed for anticoagulant monotherapy and combined therapy with antiplatelet agents. Eleven studies (6359 patients) were included. Overall, there were no differences between DOACs and VKA for all-cause mortality (Odds Ratio [OR]: .69; Credible Interval [CrI]: .40–1.06), cardiovascular-related mortality (OR: .76; Crl: .13–3.47), bleeding (OR: .95; CrI: .75–1.17), stroke (OR: 1.04; CrI: .65–1.63), myocardial infarction (OR: 1.51; CrI: .55–3.84), and valve thrombosis (OR: .29; CrI: .01–3.54). For DOACs vs VKA monotherapy subgroup, there were no differences in outcomes. For the combined therapy subgroup, there was decreased odds of all-cause mortality in the DOACs group compared with the VKA group (OR: .13; CrI: .02–.65), but no differences for bleeding and stroke. DOACs and VKA have similar safety and efficacy profiles for post-TAVI patients with anticoagulation indication. However, if concomitant antiplatelet therapy is required, DOACs were more favorable than VKA for all-cause mortality.
TarantiniGMojoliMWindeckerS, et al.Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry. JACC Cardiovasc Interv. 2016;9:937–946.
2.
AdamsDHPopmaJJReardonMJ, et al.Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–1798.
3.
VoraANDaiDMatsuokaR, et al.Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement: an analysis from the STS/ACC TVT registry. JACC Cardiovasc Interv. 2018;11:1746–1756.
4.
LeonMBSmithCRMackM, et al.Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607.
5.
GoelSSIgeMTuzcuEM, et al.Severe aortic stenosis and coronary artery disease—Implications for management in the transcatheter aortic valve replacement era: a comprehensive review. J Am Coll Cardiol. 2013;62:1–10.
6.
OttoCMNishimuraRABonowRO, et al.2020ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2021;143:e72–e227.
7.
VahanianABeyersdorfFPrazF, et al.2021 ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2022;43:561–632.
8.
UeyamaHKunoTAndoT, et al.Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists after transcatheter aortic valve implantation. Am J Cardiol. 2020;125:1102–1107.
9.
KappeteinAPHeadSJGénéreuxP, et al.Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardio Thorac Surg. 2012;42:S45–S60.
10.
BéliveauABoyneDJSlaterJBrennerDAroraP. BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses. BMC Med Res Methodol. 2019;19:196.
11.
PlummerM. JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. In: Proceedings of the 3rd International Workshop on Distributed Statistical Computing, Vienna, Austria, March 20-22, 2003.
HigginsJPTThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
14.
FletcherJ. What is heterogeneity and is it important?BMJ. 2007;334:94–96.
15.
HigginsJPTThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
16.
TufanaruCMunnZStephensonMAromatarisE. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Base Healthc. 2015;13:196–207.
17.
GünhanBKRöverCFriedeT. Random-effects meta-analysis of few studies involving rare events. Res Synth Methods. 2020;11:74–90.
18.
SedgwickP. What is publication bias in a meta-analysis?BMJ. 2015;351:h4419.
19.
GeisNAKiriakouCChorianopoulosEUhlmannLKatusHABekeredjianR. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol. 2018;107:799–806.
20.
HanssonNCGroveELAndersenHR, et al.Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68:2059–2069.
21.
KawashimaHWatanabeYHiokiH, et al.Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv. 2020;13:2587–2597.
22.
MangnerNCrusiusLHaussigS, et al.Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation. Am J Cardiol. 2019;123:1134–1141.
23.
NijenhuisVJBrouwerJDelewiR, et al.Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;382:1696–1707.
24.
SeegerJGonskaBRodewaldCRottbauerWWöhrleJ. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc Interv. 2017;10:66–74.
25.
JochheimDBarbantiMCaprettiG, et al.Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:1566–1576.
26.
KosmidouILiuYAluMC, et al.Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. JACC Cardiovasc Interv. 2019;12:1580–1589.
27.
ButtJHDe BackerOOlesenJB, et al.Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021;7:11–19.
28.
KalogerasKJabbourRJRupareliaN, et al.Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry. J Thromb Thrombolysis. 2020;50:82–89.
29.
D'AscenzoFBenedettoUBiancoM, et al.Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI. EuroIntervention. 2017;13:e1392–e4000.
30.
Abdul-Jawad AltisentODurandEMuñoz-GarcíaAJ, et al.Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2016;9:1706–1717.
31.
DangasGDTijssenJGPWöhrleJ, et al.A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–129.
32.
Rodés-CabauJMassonJBWelshRC, et al.Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–1365.
33.
CalabròPGragnanoFNiccoliG, et al.Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease. Circulation. 2021;144:1323–1343.
34.
LiangHHeQZhangQ, et al.Efficacy and safety outcomes in novel oral anticoagulants versus vitamin-K antagonist on post-TAVI patients: a meta-analysis. BMC Cardiovasc Disord. 2020;20:307.
35.
GuimarãesHPLopesRDde Barros e SilvaPGM, et al.Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383:2117–2126.
36.
ShimCYSeoJKimYJ, et al.Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg. 2021. Online ahead of print.
37.
CaldeiraDNunes-FerreiraARodriguesRVicenteEPintoFJFerreiraJJ. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr. 2019;81:209–214.
38.
SharmaAGoelSLavieCJArbab-ZadehAMukherjeeDLazarJ. Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR). J Thromb Thrombolysis. 2015;39:467–473.
39.
CapodannoDColletJ-PDangasG, et al.Antithrombotic therapy after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14:1688–1703.
40.
ShiremanTIHowardPAKresowikTFEllerbeckEF. Combined anticoagulant–antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35:2362–2367.
41.
JohnsonSGRogersKDelateTWittDM. Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest. 2008;133:948–954.
42.
GrangerCBAlexanderJHMcMurrayJJV, et al.Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
43.
PatelMRMahaffeyKWGargJ, et al.Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
44.
GiuglianoRPRuffCTBraunwaldE, et al.Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
45.
ConnollySJEzekowitzMDYusufS, et al.Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
46.
GénéreuxPCohenDJMackM, et al.Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol. 2014;64:2605–2615.
47.
DidierRLhermusierTAuffretV, et al.TAVR patients requiring anticoagulation. JACC Cardiovasc Interv. 2021;14:1704–1713.
48.
ColletJPBertiSCequierA, et al.Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J. 2018;200:44–50.
49.
ten BergJSibbingDRoccaB, et al.Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC council on valvular heart disease. Eur Heart J. 2021;42:2265–2269.
50.
KobariYInoharaTSaitoT, et al.Aspirin versus clopidogrel as single antithrombotic therapy after transcatheter aortic valve replacement: insight from the OCEAN-TAVI registry. Circ Cardiovasc Interv. 2021;14:e010097.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
